Tamoxifen Retinopathy: Retinal cavitation without crystalline deposits
Keywords:
tamoxifen, retinopathy, crystals, cavitation, breast cancerAbstract
Tamoxifen is a selective estrogen receptor modulator commonly used to treat and prevent the recurrence of estrogen receptor-positive breast cancer. Even at low doses, adverse effects have been reported such as pseudo cystic foveal cavitation, refractile crystalline deposits, and photoreceptor disruption. With the advent of modern imaging technology such as optical coherence tomography, the prevalence of tamoxifen retinopathy has been found to be greater than previously published reports. We report a case of tamoxifen retinopathy, that manifested without typical crystalline retinal deposits and a normal fundus exam, with a diagnosis being made based on clinical findings, risk factors, and multimodal imaging. A comprehensive review of the condition is also presented including pathophysiology, treatment, and multimodal imaging results.
References
Bommireddy T, Carrim ZI. To stop or not? Tamoxifen therapy for secondary prevention of breast cancer in a patient with ocular toxicity. BMJ case reports. 2016;2016:bcr2015213431. Doi:10.1136/bcr-2015-213431
Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. Mar 9 2013;381(9869):805-16. Doi:10.1016/s0140-6736(12)61963-1
Gray RG, Rea D, Handley K, et al. Attom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. Journal of Clinical Oncology. 2013/06/20 2013;31(18_suppl):5-5. Doi:10.1200/jco.2013.31.18_suppl.5
Kim HA, Lee S, Eah KS, Yoon YH. Prevalence and Risk Factors of Tamoxifen Retinopathy. Ophthalmology. Apr 2020;127(4):555-557. Doi:10.1016/j.ophtha.2019.10.038
Doshi RR, Fortun JA, Kim BT, Dubovy SR, Rosenfeld PJ. Pseudocystic foveal cavitation in tamoxifen retinopathy. Am J Ophthalmol. Jun 2014;157(6):1291-1298.e3. Doi:10.1016/j.ajo.2014.02.046
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. Oct 3 2015;386(10001):1341-1352. Doi:10.1016/s0140-6736(15)61074-1
Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep. Mar 1978;62(3):315-20.
Nadim F, Walid H, Adib J. The differential diagnosis of crystals in the retina. Int Ophthalmol. 2001;24(3):113-21.
Torrell Belzach N, Vela Segarra JI, Crespí Vilimelis J, Alhayek M. Bilateral Macular Hole Related to Tamoxifen Low-Dose Toxicity. Case Rep Ophthalmol. Copyright © 2020 by S. Karger AG, Basel.; 2020:528-533. Vol. 3.
Zamorano Martín F, Rocha-de-Lossada C, Rachwani Anil R, Borroni D, Rodriguez Calvo de Mora M, España Contreras M. Tamoxifen maculopathy: The importance of screening and long follow-up. J Fr Ophtalmol. Oct 2020;43(8):727-730. Doi:10.1016/j.jfo.2019.12.004
Early Breast Cancer Trialists' Collaborative G. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet Oncology. 2022;23(3):382-392. Doi:10.1016/S1470-2045(21)00758-0
Elias A, Gopalakrishnan M, Anantharaman G. Risk factors in patients with macular telangiectasia 2A in an Asian population: A case-control study. Indian J Ophthalmol. Sep 2017;65(9):830-834. Doi:10.4103/ijo.IJO_85_17
Venkatesh R, Reddy NG, Mishra P, et al. Spectral domain OCT features in type 2 macular telangiectasia (type 2 mactel): its relevance with clinical staging and visual acuity. Int J Retina Vitreous. Apr 5 2022;8(1):26. Doi:10.1186/s40942-022-00378-0
Farrar MC, Jacobs TF. Tamoxifen. Statpearls. Statpearls Publishing
Copyright © 2022, statpearls Publishing LLC.; 2022.
Lee S, Kim HA, Yoon YH. OCT Angiography Findings of Tamoxifen Retinopathy: Similarity with Macular Telangiectasia Type 2. Ophthalmol Retina. Aug 2019;3(8):681-689. Doi:10.1016/j.oret.2019.03.014
Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer. Jun 15 1992;69(12):2961-4. Doi:10.1002/1097-0142(19920615)69:12<2961::aid-cncr2820691215>3.0.co;2-w
Tang R, Shields J, Schiffman J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye. 1997/05/01 1997;11(3):295-297. Doi:10.1038/eye.1997.64
Therssen R, Jansen E, Leys A, Rutten J, Meyskens J. Screening for tamoxifen ocular toxicity: a prospective study. Eur J Ophthalmol. Oct-Dec 1995;5(4):230-4.
Chung H, Kim D, Ahn S-H, et al. Early Detection of Tamoxifen-induced Maculopathy in Patients With Low Cumulative Doses of Tamoxifen. Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye. 2010/03// 2010:1-5. Doi:10.3928/15428877-20100215-06
Behrens A, Sallam A, Pemberton J, Uwaydat S. Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2. Case Rep Ophthalmol. 2018:54-60. Vol. 1.
Raizman MB, Hamrah P, Holland EJ, et al. Drug-induced corneal epithelial changes. Surv Ophthalmol. May-Jun 2017;62(3):286-301. Doi:10.1016/j.survophthal.2016.11.008
Charbel Issa P, Gillies MC, Chew EY, et al. Macular telangiectasia type 2. Prog Retin Eye Res. May 2013;34:49-77. Doi:10.1016/j.preteyeres.2012.11.002
Wong WT, Forooghian F, Majumdar Z, Bonner RF, Cunningham D, Chew EY. Fundus autofluorescence in type 2 idiopathic macular telangiectasia: correlation with optical coherence tomography and microperimetry. Am J Ophthalmol. Oct 2009;148(4):573-83. Doi:10.1016/j.ajo.2009.04.030
Park YJ, Lee S, Yoon YH. One-year follow-up of optical coherence tomography angiography microvascular findings: macular telangiectasia type 2 versus tamoxifen retinopathy. Graefes Arch Clin Exp Ophthalmol. May 10 2022;doi:10.1007/s00417-022-05695-6
Heeren TF, Holz FG, Charbel Issa P. First symptoms and their age of onset in macular telangiectasia type 2. Retina. May 2014;34(5):916-9. Doi:10.1097/iae.0000000000000082
Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila). Jun 2010;3(6):696-706. Doi:10.1158/1940-6207.capr-10-0076
Rahimy E, Sarraf D. Bevacizumab Therapy for Tamoxifen-Induced Crystalline Retinopathy and Severe Cystoid Macular Edema. Archives of Ophthalmology. 2012;130(7):931-932. Doi:10.1001/archophthalmol.2011.2741
Li C, Xiao J, Zou H, Yang B, Luo L. The response of anti-VEGF therapy and tamoxifen withdrawal of tamoxifen-induced cystoid macular edema in the same patient. BMC Ophthalmology. 2021/05/07 2021;21(1):201. Doi:10.1186/s12886-021-01953-z
Zafeiropoulos P, Nanos P, Tsigkoulis E, Stefaniotou M. Bilateral macular edema in a patient treated with tamoxifen: a case report and review of the literature. Case reports in ophthalmology. 2014;5(3):451-454. Doi:10.1159/000370144
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Raman Bhakhri, Leo Jiang, Nitasha Merchant, Brittney Brady
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
